Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Standard western medicine treatment + Chaigui Longmu Paste without Ejiao is a combination therapy used as a control arm in clinical research conducted by Longhua Hospital for the treatment of ischemic heart disease (IHD). This intervention consists of conventional pharmacological treatments for IHD—typically including antiplatelet agents (e.g., aspirin), statins, and beta-blockers—combined with a modified Traditional Chinese Medicine (TCM) formulation. The TCM component, Chaigui Longmu Paste, is specifically prepared without Ejiao (donkey-hide gelatin) to serve as a parallel placebo comparator for the Ejiao-containing version (Chaigui Longmu Ejiao Paste). The TCM portion is likely based on the classical formula Chaihu Jia Longgu Mu Li Tang, which is traditionally used to soothe the liver, clear heat, and calm the spirit, addressing both physical and psychological symptoms associated with cardiovascular conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on standard western medicine treatment + Chaigui Longmu Paste without Ejiao.